Evaluating chemotherapy receipt and candidacy for PARP inhibitors in germline BRCA1/2 carriers with early and locally advanced breast cancer

被引：0
|
作者：
Wong, Stephanie
Apostolova, Carla
Ferroum, Amina
Alhassan, Basmah
Prakash, Ipshita
Basik, Mark
Martel, Karyne
Meterissian, Sarkis
Fleiszer, David
Wong, Nora
Malagon, Talia
Foulkes, William
Boileau, Jean-Francois
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO2-08-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO2-08-07
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
    Menezes, Maria Clara Saad
    Raheem, Farah
    Mina, Lida
    Ernst, Brenda
    Batalini, Felipe
    CANCERS, 2022, 14 (17)
  • [2] PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
    Frizzell, Kristine M.
    Kraus, W. Lee
    BREAST CANCER RESEARCH, 2009, 11 (06):
  • [3] PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
    Kristine M Frizzell
    W Lee Kraus
    Breast Cancer Research, 11
  • [4] Parp inhibitors for brca1/2mutation associated breast cancer
    Tutt, A. N. J.
    CANCER RESEARCH, 2022, 82 (04)
  • [5] Stage at breast cancer diagnosis is more advanced in BRCA1 carriers but not in BRCA2 carriers
    Kaufman, B.
    Lahad, A.
    Krieger, M.
    Gal, M.
    Friedman, E.
    Renbaum, P.
    Gabizon, A.
    Paluch-Shimon, S.
    Catane, R.
    Levy-Lahad, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [6] Outcomes in BRCA1/2 breast cancer patients treated with everolimus followed by chemotherapy±PARP inhibitors.
    Soliman, Hatem Hussein
    Anderson, Matthew
    Han, Hyo S.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers
    Johannsson, O
    Loman, N
    Borg, Å
    Olsson, H
    LANCET, 1998, 352 (9137) : 1359 - 1360
  • [8] Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2
    Phillips, Kelly-Anne
    Kotsopoulos, Joanne
    Domchek, Susan M.
    Terry, Mary Beth
    Chamberlain, James A.
    Bassett, Julie K.
    Aeilts, Amber M.
    Andrulis, Irene L.
    Buys, Saundra S.
    Cui, Wanda
    Daly, Mary B.
    Eisen, Andrea F.
    Foulkes, William D.
    Friedlander, Michael L.
    Gronwald, Jacek
    Hopper, John L.
    John, Esther M.
    Karlan, Beth Y.
    Kim, Raymond H.
    Kurian, Allison W.
    Lubinski, Jan
    Metcalfe, Kelly
    Nathanson, Katherine L.
    Singer, Christian F.
    Southey, Melissa C.
    Symecko, Heather
    Tung, Nadine
    Narod, Steven A.
    Milne, Roger L.
    Kathleen Cuningham Foundation Consortium Research Into Familial Breast Cancer
    Risk Factor Analysis Hereditary Breast Ovarian Cancer Study
    Basser Center
    University Pennsylvania Registry
    Breast Cancer Family Registry
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (04) : 422 - 431
  • [9] Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2
    Jernström, H
    Lerman, C
    Ghadirian, P
    Lynch, HT
    Weber, B
    Garber, J
    Daly, M
    Olopade, OI
    Foulkes, WD
    Warner, E
    Brunet, JS
    Narod, SA
    LANCET, 1999, 354 (9193) : 1846 - 1850
  • [10] PARP inhibitors for hereditary breast cancer with germline BRCA mutation
    Im, Seock-Ah
    ANNALS OF ONCOLOGY, 2022, 33 : S423 - S423
12345